Articles On Imugene (ASX:IMU)

Dimerix ACTION3 Phase 3 trial successfully passes first interim analysis endpoint Mesoblast says US FDA supports accelerated approval pathway for rexlemestrocel-L Imexhs raises $1.5 million in cap raise to sophisticated and institutional i...

Highlights Phase 1 clinical trial of onCARlytics has moved to the combination arm based on the recommendation of the Cohort Review Committee (CRC). No safety issues were reported in the monotherapy arm of the trial. In the combination...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

A medical mission to flesh out and kill cancerous tumours in humans has received a boost after Imugene intravenously dosed its first patient diagnosed with bile tract cancer as part of a clinical trial.

ASX 200 tech stock Data#3 Limited (ASX: DTL) is floundering on Thursday, down 10.79% to $8.73. The drop follows the release of the business technology solutions company's 1H FY24 report. It was only two days ago that the ASX 200 tech st...

Highlights The first patient has been dosed in the intravenous monotherapy arm of the Phase 1 onCARlytics trial. The patient has been dosed at City of Hope, California. The trial targets to recruit 52 patients with metastatic or advan...

Clinical stage immuno-oncology company Imugene (ASX: IMU) has dosed the first patient in the intravenous monotherapy arm of its Phase 1 clinical trial of CD19 oncolytic virotherapy drug candidate onCARlytics. Known as OASIS, the first-in-cl...

    ASX to bounce back after a tech rally in New York Lyft jumps 35pc despite hiccup in earnings release Magnificent Seven over, now time for Sensational Six? The ASX is poised to bounce back on Thursday after a tech rally on Wall Street...

Highlights Positive early signs reported in Phase 1 MAST trial of VAXINIA. VAXINIA received Fast Track Designation from the US FDA for bile duct cancer. In Phase 1 trial for onCARlytics, first patient has been dosed. Phase 1b trial f...

Highlights Oncolytic virus CF33-hNIS (VAXINIA) is IMU’s lead candidate. CF33 and the MAST trial design and targets were presented at international event, ASCO GI Cancers Symposium. Preliminary data has demonstrated encouraging anti-tu...

Highlights First patients dosed in higher dose cohorts, cohort 5 of intratumoral and intravenous monotherapy arm. To date, 24 patients have been dosed in monotherapy arms and no safety issues have been reported. Across both monotherap...

Highlights As of 12 Jan, 38 patients have been dosed with CF33-hNIS virus under the Phase 1 VAXINIA study. The data to be presented this week at ASCO-GI shows that seven gastrointestinal cancer patients who were administered with CF33-...

Highlights IMU is focused on advancing four platform technologies , Allo CAR T cell Therapy, CF33 Oncolytic Virus, onCARlytics and B Cell Immunotherapy. The company is backed by an experienced management team with over 150 years of com...

Many of Australia's top brokers have been busy adjusting their financial models again, leading to the release of a number of broker notes this week. Three ASX shares brokers have named as buys this week are listed below. Here's why they ar...

It's been a tough year for Healius Ltd (ASX: HLS) shares. This ASX 200 healthcare stock has had an exceptionally rough 2023. Until last Wednesday, Healius had lost over 55% over the year to date. The company has had a bit of a bounce-back...

The US Food and Drug Administration has stamped Imugene’s “Vaxinia” virus trials aimed at treating bile duct cancer with “fast-track” status, providing a suite of crucial review and approval priorities.

Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.39% to 7,015.20. Markets @ Midday: Listen here at lunchtime or find all Market Matters Podcasts on Spotify...

The ASX benchmark has ended Tuesday higher 8 of 11 sectors in the green Small caps led by Plenti Group (ASX:PLT), InteliCare (ASX:ICR) The local market has trimmed some of its early gains (wussed out) after jumping out of the blocks in...

It's been a far rosier session for the S&P/ASX 200 Index (ASX: XJO) this Tuesday than what we saw yesterday. In contrast to Monday's rough start to...

Shares rebounded on Tuesday due to gains in real estate and gold, while the Australian dollar reached a four-month high amid expectations of prolonged high borrowing costs compared to other developed nations. Despite a surprise 0.2 percent...

The ASX200 has continued to gather early gains and is up nearly half a per cent – with every sector – except energy – trading in the green. Real estate stocks are strongest today, gaining 1.45 per cent. Energy’s lagging, dropping about .65...

The S&P/ASX 200 Index (ASX: XJO) is back on form on Tuesday. In afternoon trade, the benchmark index is up 0.5% to 7,020.1 points. Four ASX shares that are rising more than most are listed below. Here's why they are climbing: Collins...

I'm a firm believer in the philosophy that the best time to invest in ASX shares was probably yesterday. Most of us like to think that we can be successful with investing by buying low and selling high. But the reality is that trying to ti...

Clinical-stage immuno-oncology company Imugene (ASX: IMU) has received fast-track designation from the US Food and Drug Administration (FDA) for a clinical program to evaluate the effect of novel cancer-killing virus CF33-hNIS (Vaxinia) on...

28 Nov 2023 - A snapshot of the stocks on the move, featuring Namoi Cotton (ASX:NAM), Imugene (ASX:IMU) and Beston Global Food (ASX:BFC).

Retail sales in October declined by 0.2% compared to September, falling short of the expected 0.1% increase, indicating that rising borrowing costs and elevated inflation are impacting consumers' spending. However, over the 12-month period...

Link Administration Holdings Ltd (ASX: LNK) shares are catching the eye on Tuesday. In morning trade, the ASX 200 administration services company's shares are up 10% to $1.31. Why is this ASX 200 share jumping? Investors have been fighting...

Imugene (ASX:IMU) reaches a milestone in its MAST clinical program using its novel cancer-killing virus, Vaxinia, receiving fast-track designation from the US FDA Fast-track designation enables closer collaboration between Imugene and th...

Highlights The US FDA awarded Fast Track designation to clinical program studying VAXINIA in bile duct cancer. This designation enables enhanced collaboration with the FDA, facilitating the expedited progress of the MAST clinical progr...

  Namoi Cotton (ASX:NAM) has received a non-binding, indicative and conditional offer (NBIO) from Louis Dreyfus Company Asia to acquire the remaining 83% of issued shares in Namoi that it does not currently own, by way of a scheme of arrang...

The Collins Foods Ltd (ASX: CKF) share price is having a strong session. In morning trade, the quick service restaurant operator's shares are up 10% to a 52-week high of $11.16. This follows the release of the ASX 200 stock's half-year res...

The Pointsbet Holdings Ltd (ASX: PBH) share price is marching higher today. Shares in the All Ordinaries Index (ASX: XAO) sports betting company closed flat yesterday at 73 cents. In morning trade on Tuesday, shares are swapping hands for...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The Imugene Limited (ASX: IMU) share price is charging higher on Tuesday morning. At the time of writing, the immuno-oncology company's shares are up 32% to 12 cents. Why is the Imugene share price charging higher? Investors have been buyi...

ASX futures were largely flat near 8:30 AEDT, up only 0.08 per cent (6pts). The ASX200 could go either way. The S&P 500 finished down 0.20 per cent; the NASDAQ down 0.07 per cent. Looking at Australian economic data, we get retail...

The ASX offers some great opportunities for investors to build a reliable passive income stream. Many leading ASX companies also offer franked dividends, giving investors potential tax benefits on the extra income they earn. Now, I've anal...

Fixed income ASX ETFs could be a good asset class to look at to invest in right now. If readers aren't sure what bonds are, they should read the linked explainer. Basically, it's investing in a slice of the debt issued by a government or c...

The Sayona Mining Ltd (ASX: SYA) share price is down 1.3% to 7.6 cents on Wednesday. It's a poor day for ASX lithium shares today, with Sayona's counterparts also struggling. Here are some examples: Latin Resources Ltd (ASX: LRS) shar...

The Avita Medical Inc (ASX: AVH) share price is having a tough morning. At the time of writing, the regenerative medicine company's shares are down 14% to $3.29. Why is the Avita Medical share price sinking? Investors have been heading to...

ASX lithium shares have been flogged to death as an investment theme the last few years, so are there any real bargains left any more? It may surprise you that there definitely are. The global price for the battery ingredient has significa...

The Wildcat Resources Ltd (ASX: WC8) share price is trading at 81 cents on Friday, down 19.8% from its 15-year high of $1.01 reached last Monday. Is this an opportunity to buy the dip? Let's review what's been happening with the Wildcat...

The Azure Minerals Ltd (ASX: AZS) share price is slightly higher on Friday amid a major shareholder's assertion that the junior explorer's takeover by a Chilean lithium giant appears unlikely to proceed. Azure shares are currently trading...

Mineral Resources Ltd (ASX: MIN) shares closed the session at $62.60 per share, down 0.32% amid the company hosting its annual general meeting (AGM) today. The S&P/ASX 200 Index (ASX: XJO) closed lower as well, down 0.67%. MinRes see...

It's a fact of investing life that there will always be another stock market crash. Market crashes come around every few years on the ASX. They are not pleasant, but they are inevitable. That's why it's always a good idea to plan ahead for...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

The local share market Is tipped to make its greatest gains in over a month, with ASX futures suggesting a rise of just under 1.3 per cent. That’s thanks to action on US markets overnight, the NASDAQ shot up more than 2.5 per cent, The S...

Sayona Mining Ltd (ASX: SYA) shares have seen their fair share of ups and downs over the past three years. Well, more than their fair share really, as you can see on the price chart below. Sayona Mining shares got a huge boost from mid-202...

ASX lithium share Mineral Resources Ltd (ASX: MIN) is trading at $60.30 per share, up 3.93% on Tuesday afternoon. Meantime, the S&P/ASX 200 Index (ASX: XJO) is up 0.89% at the time of writing. Much weaker lithium commodity prices in 2...

The Avita Medical Inc (ASX: AVH) share price is having a banner day. Shares in the ASX healthcare stock closed yesterday trading for $3.56. In morning trade on Tuesday, shares were swapping hands for $4.16, up a whopping 16.9%. After what...